A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

N/ACompletedNCT01974232

Weill Medical College of Cornell University33 enrolled

Overview

This is a retrospective analysis of children (≤21years old) who received clinical treatment with either Romiplostim or Eltrombopag at 2 medical centers from 2009-2013. The children included in this study were from Weill Medical College of Cornell University, New York, New York and Children's Hospital Orange County, Orange, California

Study Type

OBSERVATIONAL

Enrollment

Conditions

Immune Thrombocytopenia

Eligibility

Sex: ALLMin age: 19 MonthsMax age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1\. All patients in this study had received prior treatments before the start of TPO treatment including corticosteroids, IVIG, IV anti-D, and/or Rituximab. Exclusion Criteria: 1\. Children who do not have ITP

Locations (1)

Weill Cornell Medical College

New York, New York, United States

Outcomes

Primary Outcomes

Platelet count greater than or = to 50,000

Time frame: on two consecutive weeks

Secondary Outcomes

An increase in platelets greater than or = to 20,000 over baseline.

Time frame: On two consecutive weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.